Safe Method to Create Diabetic Monkey Models Using Single Dose of Standard-Grade STZ
A single 100 mg/kg dose of analytical-grade streptozotocin safely induced complete diabetes in cynomolgus monkeys without liver or kidney damage.
Quick Facts
What This Study Found
Single 100 mg/kg dose of analytical-grade STZ induced complete diabetes in cynomolgus monkeys with destroyed beta cells and <0.5 ng/mL stimulated C-peptide, without organ toxicity.
Key Numbers
100 mg/kg STZ IV; C-peptide <0.5 ng/mL; triphasic blood glucose response; no vomiting or organ toxicity
How They Did This
3 cynomolgus monkeys received IV STZ (100 mg/kg over 5 min). Blood glucose monitored hourly for 48h then twice daily. C-peptide by ELISA; liver/renal function blood chemistry; islet immunohistochemistry for insulin and glucagon.
Why This Research Matters
Primate diabetes models are essential for testing islet transplants and peptide-based diabetes drugs. This accessible method removes the barrier of needing expensive clinical-grade STZ.
The Bigger Picture
Better primate diabetes models accelerate development of diabetes therapies including GLP-1 agonists, insulin analogs, and islet transplantation approaches.
What This Study Doesn't Tell Us
Only 3 animals — very small sample; no long-term follow-up reported; single STZ source tested; model represents type 1 (beta cell destruction), not type 2 diabetes.
Questions This Raises
- ?Is this method reproducible across different batches of analytical-grade STZ?
- ?How long does the diabetes model remain stable for long-term drug studies?
- ?Would lower doses achieve partial beta cell destruction for a type 2-like model?
Trust & Context
- Key Stat:
- 3/3 complete diabetes All three monkeys achieved complete diabetes with no adverse organ effects from a single STZ dose
- Evidence Grade:
- Low — proof-of-concept with only 3 animals and no control group; adequate for method validation but limited for generalization.
- Study Age:
- Published in 2020; STZ diabetic models remain standard in primate diabetes research.
- Original Title:
- Induction of diabetes in cynomolgus monkey with one shot of analytical grade streptozotocin.
- Published In:
- Animal models and experimental medicine, 3(1), 79-86 (2020)
- Authors:
- Liu, Zhengzhao, Lu, Ying(4), Hu, Wenbao, Hara, Hidetaka, Dai, Yifan, Cai, Zhiming, Mou, Lisha
- Database ID:
- RPEP-04964
Evidence Hierarchy
Frequently Asked Questions
Why use monkeys for diabetes research?
Monkey physiology is much closer to humans than rodents, making primate models more predictive for testing diabetes drugs and islet transplantation before human trials.
What does streptozotocin do?
STZ selectively destroys insulin-producing beta cells in the pancreas, creating a model of diabetes that closely mimics type 1 diabetes for research purposes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04964APA
Liu, Zhengzhao; Lu, Ying; Hu, Wenbao; Hara, Hidetaka; Dai, Yifan; Cai, Zhiming; Mou, Lisha. (2020). Induction of diabetes in cynomolgus monkey with one shot of analytical grade streptozotocin.. Animal models and experimental medicine, 3(1), 79-86. https://doi.org/10.1002/ame2.12109
MLA
Liu, Zhengzhao, et al. "Induction of diabetes in cynomolgus monkey with one shot of analytical grade streptozotocin.." Animal models and experimental medicine, 2020. https://doi.org/10.1002/ame2.12109
RethinkPeptides
RethinkPeptides Research Database. "Induction of diabetes in cynomolgus monkey with one shot of ..." RPEP-04964. Retrieved from https://rethinkpeptides.com/research/liu-2020-induction-of-diabetes-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.